Shares of Virax Biolabs (NASDAQ: VRAX) popped in morning trading on Thursday after the biotechnology company announced the launch and distribution of an RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit in markets like the European Union (EU), which accept the CE mark.
The test kits are for use in both at-home and in point-of-care settings with results usually available in 15 minutes.
